<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta name="generator" content="Hugo 0.18.1" />


<title>Disciplined approach to drug discovery and early development - A Hugo website</title>
<meta property="og:title" content="Disciplined approach to drug discovery and early development - A Hugo website">



  







<link rel="stylesheet" href="../../../../css/fonts.css" media="all">
<link rel="stylesheet" href="../../../../css/main.css" media="all">



  </head>
  <body>
    <div class="wrapper">
      <header class="header">
        <nav class="nav">
  <a href="../../../../" class="nav-logo">
    <img src="../../../../images/logo.png"
         width="50"
         height="50"
         alt="Logo">
  </a>

  <ul class="nav-links">
    
    <li><a href="../../../../about/">About</a></li>
    
    <li><a href="https://github.com/rstudio/blogdown">GitHub</a></li>
    
    <li><a href="https://twitter.com/rstudio">Twitter</a></li>
    
  </ul>
</nav>

      </header>


<main class="content" role="main">

  <article class="article">
    
    <span class="article-duration">8 min read</span>
    

    <h1 class="article-title">Disciplined approach to drug discovery and early development</h1>

    
    <span class="article-date">0001/01/01</span>
    

    <div class="article-content">
      

<p>오늘 논문 발표 한 내용을 올립니다.</p>

<h1 id="introduction">INTRODUCTION</h1>

<h2 id="decrease-in-r-d-productivity">Decrease in R&amp;D productivity</h2>

<h3 id="r-d-costs-continue-to-rise">R&amp;D costs continue to rise</h3>

<ul>
<li>The median cost of developing any NTD from phase 1 clinical trials to approval is \$250 million</li>
<li>Only 10% of drugs tested in phase 1 are ultimately approved</li>
<li>The total R&amp;D cost to well more than \$2.5 billion for every NTD approved</li>
</ul>

<h3 id="major-driver-of-cost">Major driver of cost</h3>

<ul>
<li><strong>Failure to achieve safety or efficacy</strong> in phase 2 and phase 3 trials</li>
<li><strong>key contributor</strong> to the decline in R&amp;D productivity.</li>
</ul>

<hr />

<div align = center><img src=asset/DrugFail.jpg width = 1000/></div>

<h2 id="late-phase-predictions">Late phase predictions</h2>

<h3 id="failure">Failure</h3>

<ul>
<li>Preclinical models

<ul>
<li>Poor predictive value of preclinical models correlates with lack of efficacy in phases 2 and 3</li>
</ul></li>
</ul>

<h3 id="success">Success</h3>

<ul>
<li>Drug targets based on human genetic diseases

<ul>
<li>More likely to achieve success</li>
</ul></li>
<li>“fail fast” strategy

<ul>
<li>Small clinical trials that test PoC</li>
<li>Reduce phase 2 and phase 3 attrition rates</li>
</ul></li>
</ul>

<h2 id="decline-in-r-d-productivity">Decline in R&amp;D productivity</h2>

<ul>
<li>3-year rolling averages for late-stage pipeline (estimates of peak sales)

<ul>
<li>Decreased by nearly 50% over the past 5 years</li>
<li>From \$692 million (during the period from 2010 to 2012)</li>
<li>To \$451 million (2013 to 2015)</li>
</ul></li>
</ul>

<hr />

<div align = center><img src=asset/fig1.png width = 1024/></div>

<h1 id="i-causal-human-biology">I. CAUSAL HUMAN BIOLOGY</h1>

<div align = center><img src=http://i.makeagif.com/media/7-04-2015/PfdTOW.gif height = 300/></div>

<h2 id="definition-of-good-drug">Definition of good drug</h2>

<ul>
<li>“Good” drug

<ul>
<li>One that <strong>binds to and modulates a molecular target in such a way that is safe and effective</strong> in the disease context for which it is administered.</li>
<li>Safety-efficacy profiles and dose-response curves</li>
</ul></li>
</ul>

<h2 id="physiological-outcome">Physiological outcome</h2>

<ul>
<li>Target modulation is <strong>causally related</strong> to a physiological outcome</li>
<li>Naturally occurring biologic perturbations that lead to changes in human physiology

<ul>
<li>Clues into the mechanisms by which new therapies might work</li>
</ul></li>
<li>Goal of drug R&amp;D is to <strong>develop therapies that mimic experiments of nature</strong></li>
<li><strong>These causal relationships should be established at the time a target is selected</strong></li>
</ul>

<h2 id="infectious-diseases">Infectious diseases</h2>

<ul>
<li>Infections of the lungs or skin

<ul>
<li>Pneumonia</li>
<li>Cellulitis</li>
</ul></li>
<li>Other diseases that were not considered initially to result from an infectious agent

<ul>
<li>Helicobacter pylori as a cause of gastric ulcers</li>
<li>Human papillomavirus as a cause of cervical cancer</li>
</ul></li>
<li>Therapeutic interventions against these infectious agents have a documented benefit on human health, which provides a modern-day test of Koch’s postulates.</li>
</ul>

<h2 id="genetics-and-tissue-specific-autoimmunity">Genetics and tissue-specific autoimmunity</h2>

<ul>
<li><code>Experiments of nature</code></li>
<li>Approved antipsychotic medications block <strong>dopamine receptor D2 (DRD2)</strong> and treat the positive symptoms in patients with schizophrenia.</li>
<li>GWAS

<ul>
<li>Identified genetic variation in the DRD2 gene locus (increased risk)</li>
</ul></li>
</ul>

<hr />

<div align = center><img src=asset/table1.png height = 550/></div>

<h2 id="ongoing-large-scale-sequencing-efforts">Ongoing large-scale sequencing efforts</h2>

<ul>
<li><strong>genomes are linked to detailed clinical data</strong></li>
<li>Genotype-phenotype dose-response curves can be estimated <strong>at the start of a drug discovery program</strong></li>
<li>Gain of function (GoF) and loss of function (LoF), including “human knockouts”

<ul>
<li>Linked to clinical data that can be mined to estimate the <strong>effect of lifelong genetic perturbation on human physiology</strong></li>
</ul></li>
</ul>

<h2 id="single-cell-technologies">Single-cell technologies</h2>

<ul>
<li>Possible to identify antigens that drive the human immune response to infectious diseases, autoimmune disorders</li>
</ul>

<h3 id="examples">Examples</h3>

<ul>
<li>Neutralizing antibodies that recognize the <strong>hemagglutinin glycoprotein antigen from influenza A virus</strong> have been identified</li>
<li>Antibodies against DRD2 in patients with schizophrenia</li>
</ul>

<h2 id="animal-models-limitations">Animal models - Limitations</h2>

<h3 id="valuable">Valuable</h3>

<ul>
<li>Understanding of complex physiology, testing pharmacology, and assessing safety</li>
</ul>

<h3 id="lesson">Lesson</h3>

<ul>
<li><strong>animal models should not be used to pick targets at the beginning of a drug discovery program</strong></li>
<li>Targets should be selected on the basis of a <strong>deep understanding of causal human biology</strong>, not on the basis of imperfect and notoriously inaccurate animal model data, whether causal or correlative.</li>
</ul>

<hr />

<div align = center><img src=asset/fig1.png width = 1024/></div>

<h1 id="ii-therapeutic-modulation">II. THERAPEUTIC MODULATION</h1>

<div align = center><img src=http://i.makeagif.com/media/7-04-2015/PfdTOW.gif height = 300/></div>

<h2 id="therapeutic-modulation-two-major-challenges">Therapeutic modulation - Two major challenges.</h2>

<h3 id="1-therapeutic-molecule-must-gain-access-to-the-protein-target">1. therapeutic molecule must gain access to the protein target</h3>

<ul>
<li>Only ~20% of human proteins are accessible by either small molecules (which target hydrophobic pockets) or biological therapeutics (which bind to extracellular targets), which leaves most protein targets “undruggable” .</li>
</ul>

<h3 id="2-it-must-exert-an-effect-consistent-with-the-underlying-therapeutic-hypothesis">2. it must exert an effect consistent with the underlying therapeutic hypothesis.</h3>

<ul>
<li>As a consequence, only a small portion of potential drug targets is considered therapeutically tractable for a new drug discovery program.</li>
</ul>

<h2 id="therapeutic-modulation-causal-human-biology">Therapeutic modulation - causal human biology</h2>

<h3 id="directionality-of-the-desired-therapeutic-modulation">Directionality of the desired therapeutic modulation</h3>

<ul>
<li>Therapeutically desirable to increase or decrease activity of protein target</li>
<li>Altering enzymatic activity, ligand-induced receptor signaling, or transcriptional regulation).</li>
</ul>

<h3 id="examples-1">Examples</h3>

<ul>
<li>Narcolepsy

<ul>
<li>Autoimmune destruction of a specific cell type that secretes a specific protein ligand</li>
<li>Obliteration of neurons that secrete wakefulness-inducing orexin in patients with narcolepsy</li>
</ul></li>
</ul>

<h2 id="limitation-of-druggability-so-far">Limitation of druggability so far</h2>

<ul>
<li>Selected on the basis of <strong>tractability (or druggability) rather than causal human biology</strong></li>
<li>Many targets identified by human genetics or other experiments of nature <strong>might not be considered druggable</strong> by either conventional small molecules or biologics</li>
</ul>

<h3 id="example-gba">Example - GBA</h3>

<ul>
<li>Glucocerebrosidase (GBA), a lysosomal enzyme–encoding gene

<ul>
<li>Gaucher disease, Parkinson’s disease</li>
</ul></li>
<li>GBA breaks down glucocerebroside into glucose and ceramide, a fat molecule</li>
<li>As an intracellular protein

<ul>
<li>Not accessible via conventional antibody-based biologics</li>
<li>Also challenging to achieve with a small molecule, indicating that a new approach to GBA targeting is needed</li>
</ul></li>
</ul>

<h2 id="overcoming-undruggable-genome">overcoming &ldquo;undruggable genome&rdquo;</h2>

<h3 id="beyond-small-molecules-and-monoclonal-antibodies">beyond small molecules and monoclonal antibodies</h3>

<ul>
<li>Positive allosteric modulators</li>
<li>Conjugated nanobodies that bind different epitopes of a single target</li>
<li>Phenotypic screens</li>
<li>MRNA delivery</li>
<li>Small interfering RNA</li>
<li>Antisense oligonucleotides</li>
<li>Gene editing with CRISPR</li>
<li>Peptides</li>
</ul>

<hr />

<div align = center><img src=asset/fig1.png width = 1024/></div>

<h1 id="iii-biomarkers-of-target-modulation">III. BIOMARKERS OF TARGET MODULATION</h1>

<h2 id="what-is-biomarker">What is biomarker?</h2>

<ul>
<li>One of the most difficult aspects of drug discovery

<ul>
<li>Making robust predictions about how drug concentration in the blood relates to the final clinical outcome<br /></li>
</ul></li>
<li>The term “biomarker”

<ul>
<li>Biological readouts along the chain of events from the time a drug is exposed to the target (target exposure),</li>
<li>Engages with the target (target engagement),</li>
<li><strong>modulates the target to exert a physiological effect in a human system (target modulation)</strong>.</li>
</ul></li>
</ul>

<h2 id="pd-marker">PD marker</h2>

<ul>
<li>Most valuable pharmacodynamic biomarkers

<ul>
<li>Integrate blood and tissue <strong>pharmacokinetics</strong></li>
<li>Target engagement into a biological readout that is <strong>feasible to measure</strong> in a clinical trial</li>
</ul></li>
<li>Conventional PD marker

<ul>
<li>Pharmacological perturbation on a biological system, but these measurements have <strong>no connection to disease-specific causal human biology</strong></li>
</ul></li>
<li>In the translational medicine model proposed herein, a key step is to <strong>identify biomarkers that robustly measure the same physiological outcomes induced by experiments of nature</strong> in humans</li>
</ul>

<hr />

<div align = center><img src=asset/fig2.png width = 800/></div>

<h2 id="ldl">LDL</h2>

<ul>
<li>Low-density lipoprotein (LDL) cholesterol</li>
<li><strong>example of a robust pharmacodynamic biomarker</strong> linked to <strong>causal human biology</strong> through <strong>genetic association</strong> at the PCSK9 gene</li>
<li>Human PCSK9 genetic variants that give rise to lower LDL cholesterol protect from risk of cardiovascular disease</li>
<li>One important reason that the FDA approved two PCSK9 inhibitors

<ul>
<li>Alirocumab and evolocumab</li>
<li>LDL reduction is an accurate efficacy biomarker for protection against cardiovascular events</li>
</ul></li>
</ul>

<h2 id="pharmacodynamic-biomarkers-linked-with-causal-human-biology">pharmacodynamic biomarkers linked with causal human biology</h2>

<ul>
<li>Population-based resources</li>
<li><strong>link genetic data to deep, longitudinal molecular profiling and clinical data</strong> are being established</li>
<li>United States–led Precision Medicine Initiative)</li>
</ul>

<hr />

<div align = center><img src=asset/fig1.png width = 1024/></div>

<h1 id="iv-next-generation-poc-trials">IV. NEXT-GENERATION POC TRIALS</h1>

<h2 id="traditional-clinical-trials">Traditional clinical trials</h2>

<ul>
<li>Clinical trials represent the <strong>ultimate</strong> test of a therapeutic hypothesis</li>
<li><strong>safety and tolerability</strong> in a phase 1 clinical study</li>
<li><strong>relationship between dose of a drug and biological activity (dose-response curves)</strong> in a phase 2 trial</li>
<li>This stage is followed by a larger phase 3 trial to assess the <strong>safety-efficacy profile</strong></li>
<li>Traditionally each phase is conducted in series</li>
</ul>

<h2 id="traditional-vs-translational">Traditional vs Translational</h2>

<h3 id="traditional-clinical-trial-framework">Traditional clinical trial framework</h3>

<ul>
<li>Infectious diseases

<ul>
<li>PoC can be achieved by observing viral-load reduction in very small cohorts of patients in phase 2</li>
</ul></li>
<li>Neurodegenerative diseases

<ul>
<li>PoC can be achieved only by observing changes in clinical outcome in phase 3 trials that involve thousands of patients</li>
</ul></li>
</ul>

<h3 id="new-clinical-trial-design-linking-these-two">New clinical trial design - Linking these two</h3>

<ul>
<li>Therapeutic modulation of targets anchored in causal human biology</li>
<li>Pharmacodynamic biomarkers of target modulation</li>
</ul>

<h2 id="next-gen-poc-trials">Next-gen POC trials</h2>

<h3 id="1-identification-of-populations">1 Identification of populations</h3>

<ul>
<li>Selected patient populations can be identified for the clinical PoC study</li>
<li>Ivacaftor in cystic fibrosis patients who carry specific genetic mutations</li>
</ul>

<h3 id="2-selection-of-pd-biomarker">2 Selection of PD biomarker</h3>

<ul>
<li>Pharmacodynamic biomarkers that are <strong>linked with causal human biology</strong></li>
</ul>

<h4 id="examples-2">Examples</h4>

<ul>
<li>In developing an influenza vaccine, an <strong>immune response to hemagglutinin glycoprotein antigens</strong> is a robust pharmacodynamic biomarker</li>
<li>As described above, <strong>LDL lowering</strong>, linked with human carriers of different PCSK9 mutations, is a powerful pharmacodynamic biomarker for PCSK9 inhibitors</li>
</ul>

<h2 id="next-gen-poc-trials-1">Next-gen POC trials</h2>

<h3 id="3-digital-health-technologies">3 Digital health technologies</h3>

<ul>
<li>Patients can be followed outside of traditional clinical units using digital health technologies</li>
</ul>

<h4 id="examples-3">Examples</h4>

<ul>
<li>“digital pills”

<ul>
<li>Metal-coated tablets that dissolve in the stomach and communicate wirelessly with a mobile device),</li>
</ul></li>
<li>Continuous monitoring devices

<ul>
<li>Glucose-sensing contact lenses</li>
</ul></li>
<li>Consumer-based laboratory testing (such as smartphone kits)</li>
</ul>

<h2 id="next-gen-poc-trials-2">Next-gen POC trials</h2>

<h3 id="4-adaptive-trial-design">4 Adaptive Trial Design</h3>

<ul>
<li>Biomarker or clinical outcomes can be used to <strong>modify</strong> the design during the trial</li>
<li>Powerful approach to connect causal human biology, biomarkers, and clinical PoC</li>
</ul>

<h4 id="examples-4">Examples</h4>

<ul>
<li>The breast cancer study I-SPY 2</li>
</ul>

<h1 id="v-limitations-of-the-proposed-model">V. LIMITATIONS OF THE PROPOSED MODEL</h1>

<h2 id="first-and-foremost">First and foremost</h2>

<ul>
<li>There is an <strong>underlying assumption that we have sufficient data from humans</strong>

<ul>
<li>Validation of this assumption requires an ecosystem</li>
<li>Work systematically toward building such databases</li>
</ul></li>
<li><strong>no single resource</strong> that enables systematic identification of human genetic variants linked to clinical outcomes</li>
<li><strong>no large population</strong> with detailed molecular <strong>longitudinal profiling</strong> to identify novel biomarkers</li>
</ul>

<h2 id="second">Second</h2>

<ul>
<li>Experiments of nature are <strong>rarely perfect</strong> substitutes for pharmacological interventions</li>
<li>However, a two- to threefold increase in the success rate during phase 2 or phase 3 would have substantial financial implications</li>
<li>Failing in a large phase 3 study is about 10-fold more expensive than failing in a small clinical PoC study (\$150 million versus \$15 million per NTD)</li>
</ul>

<h2 id="third">Third</h2>

<ul>
<li><strong>Some diseases do not have experiments of nature</strong> to guide target selection</li>
<li>Every complex disease is influenced by environmental, behavioral, or stochastic factors that might lead to specific therapeutic hypotheses</li>
<li>Consistent with this observation, there are many examples of approved therapies that do not have obvious evidence of causal human biology</li>
</ul>

<h2 id="fourth">Fourth</h2>

<ul>
<li><strong>Quantitative models are needed</strong> to translate causal human biology into therapeutic hypotheses that can be tested via pharmacodynamic biomarkers or clinical outcomes in small PoC trials</li>
<li>For example, human genetics might suggest that modulating a target will have a desired effect in humans, but genetic data might not indicate how much to modulate the target for a desired therapeutic window</li>
</ul>

<h2 id="fifth">Fifth</h2>

<ul>
<li><strong>New digital health technologies</strong> must enable clinical trial designs that test previously untestable therapeutic hypotheses</li>
</ul>

<h2 id="summary-and-conclusions">Summary and Conclusions</h2>

<ul>
<li>Decreased productivity in therapeutics research and development (R&amp;D)

<ul>
<li>Drug costs up while delivering insufficient value to patients</li>
</ul></li>
<li>Model of translational medicine that connects four components of the early R&amp;D pipeline

<ol>
<li>causal human biology</li>
<li>therapeutic modality</li>
<li>biomarkers of target modulation</li>
<li>proof-of-concept clinical trials</li>
</ol></li>
<li>Technological advances and a disciplined approach</li>
<li>This translational medicine approach will not eliminate all late-stage R&amp;D failures—</li>
<li>Drug discovery is an inherently risky business, after all—but it should help</li>
</ul>

<h2 id="thank-you-감사합니다">Thank you. 감사합니다.</h2>

    </div>
  </article>

  


</main>

      <footer class="footer">
        <ul class="footer-links">
          <li>
            <a href="../../../../index.xml" type="application/rss+xml" target="_blank">RSS feed</a>
          </li>
          <li>
            <a href="https://gohugo.io/" class="footer-links-kudos">Made with <img src="../../../../images/hugo-logo.png" width="22" height="22"></a>
          </li>
        </ul>
      </footer>

    </div>
    

    
<script src="../../../../js/math-code.js"></script>
<script type="text/x-mathjax-config">
MathJax.Hub.Config({
  tex2jax: {
    inlineMath: [['$','$'], ['\\(','\\)']],
    processEscapes: true
  }
});
</script>
<script async src="//cdn.bootcss.com/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML"></script>


    
  </body>
</html>

